G1 Therapeutics Inc (NASDAQ:GTHX)’s traded shares stood at 13.0 million during the latest session, with the company’s beta value hitting 1.77. At the last check today, the stock’s price was $5.66, to imply an increase of 31.93% or $1.37 in intraday trading. The GTHX share’s 52-week high remains $5.00, putting it 11.66% up since that peak but still an impressive 80.92% since price per share fell to its 52-week low of $1.08. The company has a valuation of $295.90M, with an average of 1.13 million shares over the past 3 months.
G1 Therapeutics Inc (NASDAQ:GTHX) trade information
After registering a 31.93% upside in the latest session, G1 Therapeutics Inc (GTHX) has traded red over the past five days. The stock hit a weekly high of 6.03, jumping 31.93% in its intraday price action. The 5-day price performance for the stock is 27.48%, and 21.72% over 30 days. With these gigs, the year-to-date price performance is 85.57%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
G1 Therapeutics Inc (GTHX) estimates and forecasts
Looking at statistics comparing G1 Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. G1 Therapeutics Inc (GTHX) shares are 260.50% up over the last 6 months, with its year-to-date growth rate higher than industry average at 40.86% against 13.30%. The rating firms project that company’s revenue will shrink -11.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 16.45M. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 18.17M.Earnings reports from the last fiscal year show that sales brought in 42.39M and 12.3M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -61.20% before jumping 47.70% in the following quarter.
GTHX Dividends
G1 Therapeutics Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. G1 Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
